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Condensation 10 
Alloimmunized women with a known K-positive fetus and a titer of 4 or higher need 11 
intensive clinical monitoring. 12 
Short Title 13 
Laboratory tests for predicting anti-Kell mediated HDFN 14 
Implications and contributions 15 
A. To assess the performance of anti-K titer and ADCC measurements in K-alloimmunized 16 
pregnancies with a K-positive fetus, to predict severe hemolytic disease of the fetus and 17 
newborn (HDFN) requiring transfusion therapy.  18 
B. The first titer with a cut-off value of 4 has the best diagnostic accuracy to select 19 
pregnancies at risk for severe HDFN. The ADCC test has no additional value to the titer.  20 
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C. This 16 year unselected cohort actualize that severe K-mediated HDFN can occur with 1 
low titers, the importance of fetal K-typing in selection of high risk cases and shows that 2 
the K-titer is not changing significantly during pregnancy.   3 
 4 
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Abstract 1 
Background: There is controversy on critical cut-off values of laboratory testing to select 2 
pregnancies at increased risk for anti-Kell (K) mediated HDFN (hemolytic disease of the fetus 3 
and newborn). Without early detection and treatment, Anti-K mediated HDFN may result in 4 
progressive fetal anemia, fetal hydrops, asphyxia and perinatal death.  5 
Objective: We aimed to determine the value of repeated anti-K titer determination and 6 
biological activity measurement using the antibody-dependent cellular cytotoxicity (ADCC) 7 
test determination in the management of pregnancies at risk for anti-K mediated HDFN.  8 
Study design: Retrospective cohort study of pregnancies with anti-K and a K-positive fetus, 9 
identified from January 1999 until April 2015. Laboratory test results and clinical outcome 10 
were collected from the Dutch nationwide screening program and the national reference 11 
center for fetal therapy in the Netherlands, the Leiden University Medical Center. Diagnostic 12 
accuracy (ROC-curves, sensitivity, specificity, positive and negative predictive values) of anti-13 
K titers and ADCC test. The relationship between the titer and ADCC measurements and the 14 
two foregoing measurements were computed with a Pearson product-moment correlation 15 
coefficient.  16 
Results: In a 16 year unselected cohort, representing screening results of 3.2 million 17 
pregnancies resulting in life births in the Netherlands, we identified 1,026 K-immunized 18 
pregnancies. 93 pregnant women had anti-K and a K-positive child, without other  red cell 19 
alloantibodies. Forty-nine  children (53%) needed intrauterine or postnatal transfusion 20 
therapy. The first anti-K titer showed already a high diagnostic accuracy with an AUC of 91%. 21 
The optimal cut-off point for the titer was 4 (sensitivity 100% (91-100; 95% CI), specificity 22 
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27% (15-43 95% CI) and positive predictive value 60% (49-71%). The ADCC test was not 1 
informative to select high-risk pregnancies. Linear regression showed no significant change 2 
during pregnancy, when antibody titer and ADCC test results were compared with every two 3 
foregoing measurements (p<0.0001). 4 
Conclusion(s): Early determination of the anti-K titer is sufficient to select pregnancies at 5 
increased risk for HDFN with need for transfusion therapy. If the K status of the fetus is 6 
known to be positive, a titer of 4 or higher can be used to target intensive clinical 7 
monitoring.  8 
Keywords: alloimmunization, anti-K, diagnostic accuracy, hemolytic disease of the fetus and 9 
newborn (HDFN), intra-uterine blood transfusion,  laboratory tests, red blood cell 10 
antibodies, screening program. 11 
12 
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Introduction 1 
Hemolytic Disease of the Fetus and Newborn (HDFN) is caused by red blood cell (RBC) 2 
antibodies developed by the mother and transferred to the foetus.1, 2 Kell (K) alloantibodies 3 
are second to RhD alloantibodies in importance as the cause of severe HDFN.1, 2 K 4 
alloantibodies cause hemolysis of fetal erythrocytes and also inhibit the fetal 5 
erythropoiesis.3-5 Without treatment, HDFN may result in progressive fetal anemia, fetal 6 
hydrops, asphyxia and perinatal death.6 After birth, neonatal hyperbilirubinemia may lead to 7 
‘kernicterus’, cause of neurodevelopmental impairment with athetoid cerebral palsy, 8 
hearing problems and psychomotor handicaps.7-13 Even though the incidence of fetal 9 
alloimmune hydrops has declined in the last decades,14 this condition is still a well-known 10 
risk factor for adverse perinatal and long-term outcomes.15 Severe anti-K-mediated HDFN 11 
may develop early in pregnancy, and often presents with hydrops before 20 weeks 12 
gestation.5, 15, 16 Postnatally, anti-K-mediated HDFN is characterized more frequently by 13 
anemia than by hyperbilirubinemia, compared with HDFN caused by anti-D or other type of 14 
Rh alloantibodies.6 15 
 16 
Red blood cell (RBC) alloimmunization should ideally be detected early in pregnancy upon 17 
routine RBC antibody screening. In most centers, to identify pregnancies at risk for severe 18 
HDFN, the titer of clinically relevant RBC alloantibodies is determined.1, 8, 17, 18 If the titer is 19 
above a certain threshold, patients are referred to a maternal-fetal medicine center for 20 
close surveillance and, if needed, for fetal or neonatal treatment. 17, 18 High-risk pregnancies 21 
are monitored with ultrasound and Doppler middle cerebral artery peak systolic velocity 22 
7 
 
(MCA-PSV) measurements, to predict the presence of fetal anaemia.19-21 Severe fetal 1 
anemia can be successfully treated using intrauterine transfusions (IUT). Neonates may 2 
require phototherapy or neonatal (exchange) transfusions.22  3 
In the Netherlands, fetal K (Kell) genotyping is performed with cell-free fetal DNA isolated 4 
from maternal plasma.23 K-alloimmunized pregnancies with a K-positive fetus are monitored 5 
by serial antibody titer measurements and by the Antibody Dependent Cellular Cytotoxicity 6 
(ADCC) bioassay, a monocyte based assessment of the destructive capacity of the 7 
antibodies.24-26 However, there is still controversy on which critical titers and ADCC cut-off 8 
levels indicate a high risk for anti- K-mediated HDFN.17, 18, 27-31   9 
The aim of this study was to assess the performance of anti-K titer and ADCC measurements 10 
in K-alloimmunized pregnancies with a K-positive fetus, to predict severe HDFN requiring 11 
transfusion therapy.  12 
Methods 13 
Setting and Prevention program in the Netherlands 14 
In the Netherlands, all pregnant women are typed for ABO, RhD and Rhc blood group 15 
antigens and screened for RBC antibodies at the first trimester booking visit. All screen-16 
positive samples are sent to one of two national reference laboratories for confirmation and 17 
determination of the antibody specificity. These laboratories are Sanquin Diagnostics, 18 
Amsterdam (90% of the pregnant population) and the Special Institute for Blood Group 19 
Investigations (BIBO), Groningen (10% of the pregnant population). When clinically relevant 20 
RBC antibodies are detected, i.e. antibodies with the potency to destroy fetal RBC’s, the 21 
father of the fetus is typed for the cognate antigen(s). In case the father is antigen-positive, 22 
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or his type is not known, non-invasive fetal typing with cell-free fetal DNA isolated from 1 
maternal plasma is offered (for RHD, RHC, RHc, RHE and K), since 2004. 23 If the fetus is 2 
antigen-positive, serial testing (starting with every four weeks, from 24 weeks every three 3 
weeks, from 36 weeks every two weeks) of maternal antibody titers and the ADCC test is 4 
performed. Following current Dutch guidelines, a K-antibody titer ≥ 2 and/or an ADCC-test 5 
result ≥30% indicate a substantial risk for K-mediated HDFN, and the fetus will be weekly or 6 
every two weeks monitored with MCA Doppler measurements.17  Laboratory follow-up is 7 
stopped if these thresholds are reached. Severe fetal anemia is treated with intrauterine 8 
transfusion(s) (IUT’s) at the Leiden University Medical Center (LUMC), which is the national 9 
Dutch reference center for fetal therapy. The threshold for suspected severe fetal anemia 10 
requiring IUT was 1) a MCA-PSV of 1.5 multiples of the median for gestational age (MoM), 11 
detected by Doppler measurement, and/or 2) the presence of other signs of anemia at 12 
ultrasound examination (cardiomegaly, ascites, hydrops), or 3) amniotic fluid delta optical 13 
density measurements reaching the upper part of Liley’s zone II or zone III (only in the early 14 
years of this study). 19, 32 15 
Laboratory testing 16 
Both reference laboratories assess antibody titers, in phosphate-buffered saline by doubling 17 
dilutions, with the indirect antiglobulin test (IAGT), using an anti-IgG reagent and 18 
heterozygous K-positive RBCs.33 19 
The ADCC test, as described by Engelfriet and Ouwehand, is only performed at Sanquin 20 
Diagnostics in Amsterdam.24 Fetal K typing is also only performed at Sanquin Diagnostics.23 21 
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Study design 1 
We performed a retrospective cohort study, including all pregnancies diagnosed with anti-K 2 
in the Netherlands, between January 1st 1999 and April 1st 2015. All K-immunization cases 3 
were identified at the two national reference laboratories. Women with K alloimmunization 4 
and antibody titers ≥2 and/or ADCC test results > 30%  were usually referred to the LUMC 5 
for monitoring or treatment.  All these cases could therefore also be identified in the LUMC 6 
database.  We only included pregnancies with a K-positive fetus.  7 
Outcomes  8 
The primary outcome was the diagnostic accuracy (sensitivity, specificity and predictive 9 
values) of antibody titers and ADCC tests to predict severe K-mediated HDFN, which was 10 
defined as the need for intrauterine or postnatal transfusion. 11 
Data collection 12 
We collected the results of laboratory monitoring during pregnancy from Sanquin 13 
Diagnostics and data concerning clinical monitoring and IUT treatment during pregnancy, 14 
from the LUMC databases. Neonatal outcome data on treatment with blood transfusion(s) 15 
or phototherapy during the first three months of life were extracted from their medical files, 16 
by contacting the obstetric care provider, the pediatrician or the local hospital laboratories.  17 
Analysis 18 
Categorical variables were described as number and percentage and continuous variables by 19 
median and interquartile range P25-75%. To establish the optimal cut-off for antibody titer 20 
and ADCC test results, Receiver Operating Characteristics (ROC) curves were constructed for 21 
both the first and the highest measurement. Subsequently, the sensitivity, specificity and 22 
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positive and negative predictive values for the prediction of fetal and neonatal hemolytic 1 
disease were calculated with 2x2 tables for different cut-off levels. To determine the best 2 
interval between consecutive titer and ADCC measurements, in order to adequately predict 3 
severe HDFN, a linear regression analysis (Pearson product-moment correlation coefficient) 4 
was performed. All analyses were performed with SPSS Statistics (version 23). 5 
 6 
Ethical considerations 7 
Clinical data were provided by the health care professionals as part of the quality evaluation 8 
of the routine laboratory monitoring of RBC alloantibody-complicated pregnancies The data 9 
were stored according to the Dutch established codes of conduct for responsible use of 10 
patient material and data, as approved by the Leiden University Medical Center. Ethical 11 
approval was not necessary according to the Dutch law on medical scientific research 12 
involving human subjects and according to the rules published by the Central Committee on 13 
Research involving Human Subjects (http://www.ccmo.nl/nl/niet-wmo-onderzoek).   14 
Results 15 
Study population 16 
In 16 years, 1,026 K-immunized pregnancies were identified, including three pair of twins 17 
(Figure 1). After exclusion of pregnancies with K-negative fathers (n=743) and/or K-negative 18 
fetuses/children (n=83), miscarriages (<16 weeks, n=2) and loss-to follow up (n=6), 192 19 
pregnancies with 195 K-positive fetuses remained for analysis.  In another 70 pregnancies, 20 
the K type of the father and that of the child were unknown (after 2008 all fetal K status 21 
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were known), but the absence of any sign of HDFN could be confirmed in all cases. After 1 
exclusion of these pregnancies, 124 pregnancies with 125 K-positive fetuses remained. 2 
Another seven of these 125 fetuses were excluded from our analysis, because of perinatal 3 
death, clearly not related to K-immunization (n=2) or unknown neonatal outcome (n=5). 4 
One case with severe HDFN (hydrops) detected late in pregnancy was excluded, because of 5 
lack of laboratory data. Furthermore, we excluded 24 cases with additional red cell 6 
alloantibodies, which may have contributed to the severity of HDFN.  The remaining 93 (92 7 
pregnancies) K-positive fetuses were used in our diagnostic accuracy analysis.  8 
Fifty-six percent (49/93) of children  received either intrauterine (48/93; 52%) or neonatal 9 
(1/93; 1%) transfusion, whereas the remaining 47% (44/93) had no signs of HDFN or was 10 
only treated with phototherapy . There were three cases with two pregnancies, all women 11 
had in all pregnancies titers above 4. 12 
There were three cases of perinatal death related to the K-immunization (titers variating 13 
from 128-1024). One case was closely monitored every two weeks  with ultrasound. At 23 14 
weeks the fetus was unexpectedly found to be hydropic, with an MCA Doppler result 15 
indicating fetal anemia. Fetal demise occurred just before the first IUT could be given.  One 16 
case was a very early onset of fetal anemia with hydrops detected at 15+3 weeks of 17 
gestation. The fetus died at 16 weeks; intrauterine transfusion was not performed because 18 
of the poor condition and prognosis at this early stage of the pregnancy. In the last case, the 19 
fetus was initially predicted to be K-negative with non-invasive fetal K antigen typing, at 12 20 
weeks of gestation. Awaiting the repeated and definitive K-typing result, clinical monitoring 21 
was not performed and the fetus died at 18 weeks of gestation. At 19 weeks ‘gestation, non-22 
invasive fetal K typing showed the fetus to be K-positive.  23 
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The median gestational age at the first laboratory testing was 14 weeks (P25-P75: 13-18 1 
weeks). The median gestational age at the last measurement of titer and ADCC test was 26 2 
weeks (P25-75: 18-35 weeks). The median first K-titer was 64 (P25-75: 8-256) and the 3 
highest median titer was 128 (P25-75: 16-256). The median first ADCC was 35% (P25-75: 10-4 
57.5%) and the highest median ADCC was also 35% (P25-75: 15-65%). The median number 5 
of days from the last test to the first IUT or to delivery was 26 days (P25-P75: 9-77 days). 6 
The first IUT was performed in week 24 (P25-75: 22-28 weeks). The median number of 7 
laboratory tests performed per pregnancy was 5 (P25-75: 3-8). 8 
 9 
Diagnostic accuracy of the K-antibody titer and ADCC test 10 
The ROC curves for respectively the first and the highest anti-K titer, correlating with severe 11 
HDFN, with need for transfusion therapy (n=93) The Area Under the Curve (AUC) for the first 12 
measured K antibody titer to predict the need for transfusion therapy was 0.917, for the 13 
highest titer during pregnancy the AUC was 0.906. We defined the optimal cut-off point at a 14 
sensitivity of 100% (91-100 95% CI) and combined with the highest specificity of 36% (23-52, 15 
95% CI).  Thus, an optimal cut-off for the first and highest titer was assessed at 4 (table 1).  16 
The AUC for the highest ADCC test result was 0.843. If a sensitivity of 100% was taken, the 17 
optimal cut off value appeared to be below the first test outcome of ADCC <10% (data not 18 
shown). Therefore, additional ADCC testing seems to be not informative for the prediction 19 
of severe HDFN (data not shown).  20 
13 
 
Linear correlation between consecutive measurements of titer and ADCC test 1 
Since the AUCs for the highest titer and the first titer hardly differed, we investigated 2 
whether the titer and ADCC test results changed significantly during pregnancy. Linear 3 
regression showed no significant change, when antibody titer and ADCC test results were 4 
compared with every two foregoing measurements.  A Pearson product-moment correlation 5 
coefficient was computed to assess the relationship between the titer and ADCC 6 
measurements and the two foregoing measurements (for scatterplots see appendix 1 7 
a,b,c,d). Overall, there was a strong correlation between titer and ADCC measurements with 8 
the two foregoing measurements. The small, non-clinical relevant difference between the 9 
measurements is explained for 94% and 91% (titer) and 87% and 84% (ADCC) by the two 10 
foregoing measurements (p<0.0001).  11 
Comments 12 
Main Findings 13 
In a 16 year unselected cohort, representing screening results of 3.2 million pregnancies 14 
resulting in life births in the Netherlands, we identified 93 pregnancies complicated by the 15 
presence of anti-K in the presence of a K-positive fetus.  We determined that, if the K status 16 
of the fetus is positive, an anti-K titer of 4 identifies all cases with a high risk for severe 17 
HDFN, defined as the need for intra-uterine or postnatal transfusions. Test results of both 18 
titer and ADCC-test did not change significantly during pregnancy. The first titer appeared to 19 
have the highest power to predict the necessity of transfusion therapy in K-alloimmunized 20 
pregnancies.  21 
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Strengths and weaknesses 1 
To our knowledge this is the first large registry-based cohort study, including an unselected 2 
complete population of K-alloimmunized pregnant women with a K-positive child. Most 3 
other studies included a selected group of women with an increased risk for severe HDFN, 4 
for example women referred to a regional or national referral centre.27-29  5 
In our study, 93 out of 1,026 (9%) of the K-immunized pregnancies were considered as at 6 
risk for HDFN (fetus K-positive) and included in the analysis. A weakness of our study is that 7 
the K status was not known for all fetuses; yet we think no severe cases of HDFN with need 8 
for intra-uterine transfusion were missed as they would have been referred to the LUMC. 9 
Clinical implications 10 
Overall, we observed in this unselected population, that over 50% of K-positive fetuses of K-11 
alloimmunized mothers need either intrauterine or postnatal transfusion therapy. At a cut-12 
off of 4 for the first titer the specificity is 27% and the positive predictive value for 13 
transfusion therapy is 60%. This relatively high positive predictive value implicates that 14 
transfusion therapy is needed in two out of three K-positive children of mothers with a K 15 
titer of 4 or above, and may be an argument to accept this relatively low cut-off titer. In 16 
order to fine tune the selection of high-risk cases, it would making it worthwhile to add fetal 17 
K typing to the diagnostic algorithm.  With higher cut-off  titers, for example 16, still 96% of 18 
severe cases will be followed, raising test specificity to 66% and the positive predictive value 19 
to 76%. With this cut-off titers of 16 the number of missed cases of severe HDFN is three.  20 
Our proposed optimal cut-off point of the anti-K antibody titer of 4 is only one dilution step 21 
lower than suggested by Moise et al.,  who proposed a threshold of 8. It is also lower than 22 
McKenna et al.27 who proposed a threshold of 32, based on a smaller cohort with eight 23 
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cases of severe HDFN, all with titers of >=32. In contrast, Leggat et al., including 16 K-1 
positive fetuses, and our previous study, as reported by Van Wamelen et al. including 41 K-2 
positive fetuses, reported one case each needing intrauterine transfusion therapy at anti-K 3 
titers of 2. 28, 29 These studies thus support our finding that also a low anti-K titer can be 4 
responsible for a severe course of anti-K-mediated HDFN. However, in our study only 16 5 
pregnancies of 93 cases had titers below 4, we didn’t find severe cases of HDFN in this 6 
group. Therefore K-mediated HDFN with need for transfusion therapy in cases with titers 7 
below 4 is very rare. 8 
Although titer measurements can vary between laboratories, also with established 9 
techniques, in general a comparison be made with one-fold dilution difference between 10 
observers and between laboratories. It is advised to use an indirect antiglobulin test without 11 
additives.33 Non-invasive fetal K-typing with cell-free DNA isolated from maternal plasma is 12 
not available in all countries. Fetal K-typing can be performed with DNA obtained via 13 
amniocentesis. Amniocentesis is an invasive procedure, with risks for the pregnancy and a 14 
possible rise in anti-K titers. Therefore, it should be considered, if non-invasive fetal K typing 15 
is not possible via a reference laboratory, if close monitoring of anti-K complicated 16 
pregnancies with MCA-Doppler can be used for timely detection of the occurrence of fetal 17 
anemia.   18 
We observed that the monocyte-based ADCC test was not suitable to accurately select high-19 
risk K-alloimmunized pregnancies. This might be due to the pathogenesis of anti-K-mediated 20 
HDFN, in which both the suppression of erythropoiesis and hemolysis of fetal RBC may be of 21 
importance.3, 4, 34 Recently, it was also shown that the glycoprofile of alloantibodies may 22 
influence antibody pathogenicity and therefore a putative diagnostic marker.34 Therefore, it 23 
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may be that other type of bioassays, testing such antibody characteristics, may improve test 1 
specificity.26, 35, 36 37 2 
A first step in the diagnostic algorithm, that we currently use, is non-invasive fetal K typing 3 
with cell-free DNA isolated from maternal plasma.38 Prediction of K-negativity warrants a 4 
high sensitivity of this PCR-based testing and the confirmation on sufficient levels of fetal 5 
DNA; also in our series early prediction of K-negativity was incorrect once in week 12 of 6 
pregnancy.39 Since cell-free fetal DNA levels raise in the first trimester of pregnancy,  for 7 
fetal K typing a  conclusive result can in general be provided around week 18 of pregnancy.23 8 
Conclusion 9 
To select pregnancies with an increased risk for anti-K-mediated HDFN requiring frequent  10 
monitoring to detect fetal anemia, determination of the anti-K titer once early in pregnancy 11 
is sufficient. The optimal cut-off value is a titer of 4. Following the detection of anti-K, fetal 12 
K-typing, preferably using a non-invasive method, is an important step in efficient 13 
management. In pregnancies with an anti-K titer of 4 or higher and a positive fetus, 60% of 14 
fetuses or neonates requires transfusion therapy. Since the ADCC test is not useful in the 15 
prediction of fetal hemolysis in the presence of an anti-K we recommend discontinuing its 16 
use for these pregnancies.  17 
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Table 1. Number of positive tests, sensitivity, specificity and predictive values 1 
of K-mediated pregnancies without additional antibodies to predict the need for 2 
transfusion by cut-off first titre (N=93). 3 
First titre 
Cut-off 
Positive tests  Need for transfusion 
True positive *Missed 
HDFN cases 
Sens 
% (95%-CI) 
Spec 
% (95%-CI) 
PPV 
% (95%-CI) 
NPV 
% (95%-CI) 
≥2 81 49 0 100 (91-100) 27 (15-43) 60 (49-71) 100 (70-100) 
≥4 77 49 0 100 (91-100) 36 (23-52) 64 (52-74) 100 (76-100) 
≥8 70 47 2 96 (85-99) 48 (33-63) 67 (55-78) 91 (70-98) 
≥16 62 47 2 96 (85-99) 66 (50-79) 76 (63-85) 94 (77-99) 
≥32 57 45 4 92 (80-97) 73 (57-85) 79 (66-88) 89 (73-96) 
≥64 50 43 6 88 (75-95) 84 (70-93) 86 (73-93) 86 (71-94) 
≥128 43 38 11 78 (63-88) 89 (75-96) 88 (74-96) 78 (64-88) 
*Cases with necessity for transfusion therapy that would be missed when cut-off used. 4 
 5 
  6 
 7 
 8 
  9 
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FIGURE 1: FLOWCHARTS OF INCLUSION K-IMMUNIZED PREGNANCIES WITH A K-ANTIGEN POSITIVE FETUS. 1 
 2 
APPENDIX 1: SCATTERPLOTS OF RELATION BETWEEN TITER AND ADCC MEASUREMENTS WITH THE TWO 3 
FOREGOING MEASUREMENTS. 4 
